US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading ...
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
Singer Avery has been diagnosed with a condition that's thought to affect over 10 million Americans after she began using ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback